PIVAC 22

26th–28th September 2022, Molecular Biotechnology Center, Turin, Italy

PRELIMINARY PROGRAM

Monday 26th September

08.30 –09.30 Registration
09.30 –09.45  Welcome / Conference opening
SESSION 1:TUMOR MICROENVIRONMENT AND MECHANISMS OF IMMUNE RESISTANCE AND IMMUNE MODULATIONS BY CANCER CELLS
09.45 –10.15 Talk 1: Suzanne Ostrand-Rosenberg: A unifying concept and mechanism for induction of myeloid-derived suppressor cells (MDSC)
10.15 –10.45  Talk 2: Per Thor Straten: The Exercise of TAMing the Immune system
10.45 –11.00  Proffered Paper 1
11.00 –11.15 Proffered Paper 2
11.15 –11.45 Coffee Break
11.45 –12.15  Talk 3: Paola Nisticò
12.15 –12.45 Talk 4: Federico Garrido: LOH in chromosome 6 as a major tumor immune-escape mechanism
12.45 –13.00 Proffered Paper 3
13.00 –13.15 Proffered Paper 4
13.15 –14.15 Lunch
SESSION 2: INFLUENCE OF METABOLISM AND MICROBIOTA ON TUMOR IMMUNOLOGY AND IMMUNOTHERAPY
14.15 –14.45 Talk 5: Massimiliano Mazzone: Harnessing tumor metabolism to overcome immunosuppression: A novel way to enhance the success of cancer immunotherapy
14.45 –15.15  Talk 6: Yi-Ru Yu: Mitochondrial dynamics guiding CD8 T cell anti-tumor responses
15.15 –15.45 Talk 7: Cristina Munoz Pinedo: Nutrient use by tumor cells promotes an immunosuppressive environment
15.45 – 16.45 Poster Session 1 + Coffee break
16.45 –17.15 Talk 8: Maria Rescigno: The microbiota in colorectal cancer progression
17.15 –18.45  Talk 9: Guido Grandi: Understanding the role of microbiome in cancer immunity
17.45 –18.00 Proffered paper 5
18.00 –18.15 Proffered paper 6
18.15  Welcome Reception
19.30  Cultural event for invited speakers
21.00 Dinner for invited speakers

Tuesday 27th September

SESSION 3: PROGRESS IN VACCINATION AGAINST CANCER: FROM THE BENCH TO THE BEDSIDE
09.00 –09.30 Talk 10: Craig Slingluff: Intratumoral IFNg or TLR7 agonist enhances infiltration of tumor by vaccine-induced T cells
09.30 –10.00 Talk 11: Stina Wickström: Improving ACT therapy through combination with a DC tumor vaccine and protecting NK cells and T cells against oxidative stress.
10.00 –10.30 Talk 12: Francesco Novelli: Tumor associated antigen based immunotherapy in pancreatic cancer
10.30 –10.45 Proffered Paper 7
10.45 –11.00 Proffered Paper 8
11.00 – 11.30 Coffee break
11.30 –12.00 Talk 13: Cecile Gouttefangeas: Targeting of cancer metastases with a RhoC specific vaccine
12.00 –12.30  Talk 14: Gustav Gaudernack: hTERT vaccine UV-1: Clinical efficacy, long term immunological follow up of Phase I trials and further clinical development
12.30 –13.00 Talk 15: Jolanda De Vries:
13.00 –13.15 Proffered Paper 9
13.15 –13.30 Proffered Paper 10
13.30 –14.30 Lunch
SESSION 4: STRAGIES TO IDENTIFY NOVEL IMMUNOTHERAPEUTIC TARGETS AND TO MONITOR THE IMMUNE RESPONSE
14.30 -15.00 Talk 16: Sotirios Fortis: Dynamics of TCR repertoire and immune-related genes in cancer.
15.00 –15.30 Talk 17: Rienk Offringa: Exploration of the tumor-infiltrating T-cell repertoire in pancreatic cancer at the single cell level.
15.30 –16.00  Talk 18: Pierre Coulie: T cells infiltrating bladder carcinomas treated with BCG instillations
16.00 –17.00 Poster Session 2 + Coffee break
17.00 –17.30 Talk 19: Kilian Wistuba-Hamprecht: Exploring the enigmatic role of γδ T cells in cancer
17.30 –18.00 Talk 20: Else Marit Inderberg: Immunotherapy for brain tumour: challenges and immune correlates of response
18.00 –18.15 Proffered Paper 11
18.15 –18.30  Proffered Paper 12
20.00 Social dinner

Wednesday 28th September

SESSION 5:NOVEL IMMUNOTHERAPEUTIC AND COMBINED STRATEGIES FOR CANCER TREATMENT
09.00 – 09.30 Talk 21: Gosse Adema: Glyco-immune checkpoints in cancer immunotherapy
09.30 – 10.00 Talk 22: Michael Curran: Blockade of "don't eat me" signals converts radiotherapy into a systemic immunotherapy
10.00 – 10.30 Talk 23: Johannes Vom Berg: Local Immunotherapy of Cancer with Compartment Locked Biologics
10.30 – 11.00 Coffee break
11.00 – 11.30 Talk 24: Michael Nishimura: Strategies for using TCR and CAR Transduced T cells for Cancer Immunotherapy
11.30 – 12.00 Talk 25: Dario Sangiolo: CAR-CIK lymphocytes as innovative strategy for solid tumors
12.00 – 12.15 Proffered paper 13
12.15 – 12.30 Proffered paper 14
12.30 – 12.45 Concluding remarks
12.45 – 13.45 Lunch
DSCN5208.jpg
GS6V1402.jpg

General Condiction  | Privacy